Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines

Alessandra Buja, Gino Sartor, Manuela Scioni, Antonella Vecchiato, Mario Bolzan, Vincenzo Rebba, Vanna Chiarion Sileni, Angelo Claudio Palozzo, Maria Montesco, Paolo Del Fiore, Vincenzo Baldo, Carlo Riccardo Rossi

Research output: Contribution to journalArticle

Abstract

Cutaneous melanoma is a major concern in terms of healthcare systems and economics. The aim of this study was to estimate the direct costs of melanoma by disease stage, phase of diagnosis, and treatment according to the pre-set clinical guidelines drafted by the AIOM (Italian Medical Oncological Association). Based on the AIOM guidelines for malignant cutaneous melanoma, a highly detailed decision-making model was developed describing the patient's pathway from diagnosis through the subsequent phases of disease staging, surgical and medical treatment, and follow-up. The model associates each phase potentially involving medical procedures with a likelihood measure and a cost, thus enabling an estimation of the expected costs by disease stage and clinical phase of melanoma diagnosis and treatment according to the clinical guidelines. The mean per-patient cost of the whole melanoma pathway (including one year of follow-up) ranged from €149 for stage 0 disease to €66,950 for stage IV disease. The costs relating to each phase of the disease's diagnosis and treatment depended on disease stage. It is essential to calculate the direct costs of managing malignant cutaneous melanoma according to clinical guidelines in order to estimate the economic burden of this disease and to enable policy-makers to allocate appropriate resources.

Original languageEnglish
Pages (from-to)218-224
Number of pages7
JournalActa Dermato-Venereologica
Volume98
Issue number2
DOIs
Publication statusPublished - Feb 7 2018

Fingerprint

Cost of Illness
Melanoma
Guidelines
Costs and Cost Analysis
Therapeutics
Administrative Personnel
Decision Making
Economics
Delivery of Health Care
Skin

Keywords

  • Clinical Decision-Making
  • Decision Support Techniques
  • Disease Progression
  • Disease-Free Survival
  • Guideline Adherence/economics
  • Health Care Costs/standards
  • Humans
  • Italy
  • Medical Oncology/economics
  • Melanoma/economics
  • Models, Economic
  • Neoplasm Staging
  • Practice Guidelines as Topic/standards
  • Skin Neoplasms/economics
  • Time Factors
  • Treatment Outcome

Cite this

Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines. / Buja, Alessandra; Sartor, Gino; Scioni, Manuela; Vecchiato, Antonella; Bolzan, Mario; Rebba, Vincenzo; Sileni, Vanna Chiarion; Palozzo, Angelo Claudio; Montesco, Maria; Del Fiore, Paolo; Baldo, Vincenzo; Rossi, Carlo Riccardo.

In: Acta Dermato-Venereologica, Vol. 98, No. 2, 07.02.2018, p. 218-224.

Research output: Contribution to journalArticle

@article{9a227b54ff7e418a8ef27f1612c32d13,
title = "Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines",
abstract = "Cutaneous melanoma is a major concern in terms of healthcare systems and economics. The aim of this study was to estimate the direct costs of melanoma by disease stage, phase of diagnosis, and treatment according to the pre-set clinical guidelines drafted by the AIOM (Italian Medical Oncological Association). Based on the AIOM guidelines for malignant cutaneous melanoma, a highly detailed decision-making model was developed describing the patient's pathway from diagnosis through the subsequent phases of disease staging, surgical and medical treatment, and follow-up. The model associates each phase potentially involving medical procedures with a likelihood measure and a cost, thus enabling an estimation of the expected costs by disease stage and clinical phase of melanoma diagnosis and treatment according to the clinical guidelines. The mean per-patient cost of the whole melanoma pathway (including one year of follow-up) ranged from €149 for stage 0 disease to €66,950 for stage IV disease. The costs relating to each phase of the disease's diagnosis and treatment depended on disease stage. It is essential to calculate the direct costs of managing malignant cutaneous melanoma according to clinical guidelines in order to estimate the economic burden of this disease and to enable policy-makers to allocate appropriate resources.",
keywords = "Clinical Decision-Making, Decision Support Techniques, Disease Progression, Disease-Free Survival, Guideline Adherence/economics, Health Care Costs/standards, Humans, Italy, Medical Oncology/economics, Melanoma/economics, Models, Economic, Neoplasm Staging, Practice Guidelines as Topic/standards, Skin Neoplasms/economics, Time Factors, Treatment Outcome",
author = "Alessandra Buja and Gino Sartor and Manuela Scioni and Antonella Vecchiato and Mario Bolzan and Vincenzo Rebba and Sileni, {Vanna Chiarion} and Palozzo, {Angelo Claudio} and Maria Montesco and {Del Fiore}, Paolo and Vincenzo Baldo and Rossi, {Carlo Riccardo}",
year = "2018",
month = "2",
day = "7",
doi = "10.2340/00015555-2830",
language = "English",
volume = "98",
pages = "218--224",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Medical Journals/Acta D-V",
number = "2",

}

TY - JOUR

T1 - Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines

AU - Buja, Alessandra

AU - Sartor, Gino

AU - Scioni, Manuela

AU - Vecchiato, Antonella

AU - Bolzan, Mario

AU - Rebba, Vincenzo

AU - Sileni, Vanna Chiarion

AU - Palozzo, Angelo Claudio

AU - Montesco, Maria

AU - Del Fiore, Paolo

AU - Baldo, Vincenzo

AU - Rossi, Carlo Riccardo

PY - 2018/2/7

Y1 - 2018/2/7

N2 - Cutaneous melanoma is a major concern in terms of healthcare systems and economics. The aim of this study was to estimate the direct costs of melanoma by disease stage, phase of diagnosis, and treatment according to the pre-set clinical guidelines drafted by the AIOM (Italian Medical Oncological Association). Based on the AIOM guidelines for malignant cutaneous melanoma, a highly detailed decision-making model was developed describing the patient's pathway from diagnosis through the subsequent phases of disease staging, surgical and medical treatment, and follow-up. The model associates each phase potentially involving medical procedures with a likelihood measure and a cost, thus enabling an estimation of the expected costs by disease stage and clinical phase of melanoma diagnosis and treatment according to the clinical guidelines. The mean per-patient cost of the whole melanoma pathway (including one year of follow-up) ranged from €149 for stage 0 disease to €66,950 for stage IV disease. The costs relating to each phase of the disease's diagnosis and treatment depended on disease stage. It is essential to calculate the direct costs of managing malignant cutaneous melanoma according to clinical guidelines in order to estimate the economic burden of this disease and to enable policy-makers to allocate appropriate resources.

AB - Cutaneous melanoma is a major concern in terms of healthcare systems and economics. The aim of this study was to estimate the direct costs of melanoma by disease stage, phase of diagnosis, and treatment according to the pre-set clinical guidelines drafted by the AIOM (Italian Medical Oncological Association). Based on the AIOM guidelines for malignant cutaneous melanoma, a highly detailed decision-making model was developed describing the patient's pathway from diagnosis through the subsequent phases of disease staging, surgical and medical treatment, and follow-up. The model associates each phase potentially involving medical procedures with a likelihood measure and a cost, thus enabling an estimation of the expected costs by disease stage and clinical phase of melanoma diagnosis and treatment according to the clinical guidelines. The mean per-patient cost of the whole melanoma pathway (including one year of follow-up) ranged from €149 for stage 0 disease to €66,950 for stage IV disease. The costs relating to each phase of the disease's diagnosis and treatment depended on disease stage. It is essential to calculate the direct costs of managing malignant cutaneous melanoma according to clinical guidelines in order to estimate the economic burden of this disease and to enable policy-makers to allocate appropriate resources.

KW - Clinical Decision-Making

KW - Decision Support Techniques

KW - Disease Progression

KW - Disease-Free Survival

KW - Guideline Adherence/economics

KW - Health Care Costs/standards

KW - Humans

KW - Italy

KW - Medical Oncology/economics

KW - Melanoma/economics

KW - Models, Economic

KW - Neoplasm Staging

KW - Practice Guidelines as Topic/standards

KW - Skin Neoplasms/economics

KW - Time Factors

KW - Treatment Outcome

U2 - 10.2340/00015555-2830

DO - 10.2340/00015555-2830

M3 - Article

VL - 98

SP - 218

EP - 224

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 2

ER -